Definitive Contract 75D30124C19895
Award Date
8/26/24
Potential Completion Date
9/19/24
Potential Value
$1.2M
Federal Agency
CDC Pittsburgh
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
This firm-fixed-price contract was awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, for "Airport Genomic Testing". The contract, valued at $76,575,638.04, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers at five major U.S. airports, perform on-site reverse transcription polymerase chain reaction testing, whole genome sequencing, and collect and...
This federal contract award is for a delivery order under the "Test Surge and Data Sharing Multiple Award IDIQ" issued by the Centers for Disease Control and Prevention (CDC). The prime contractor is Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract has a ceiling value of $449,761.53 and a completion date of May 15, 2025. It is a time and materials contract type, with no set-aside designation. The contract leverages Ginkgo Bioworks' expertise...
This federal contract award is for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC) for "Test Surge and Data Sharing" services. The $118 million IDIQ was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts, on September 27, 2024. The contract has an ultimate completion date of September 5, 2029. This IDIQ is not designated as a set-aside contract. The IDIQ contract leverages...
This federal contract award from the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, has a total ceiling value of $10,446,304.00. The purpose of this Cost Plus Fixed Fee contract is to have Ginkgo Bioworks serve as a TA3 SD2 performer, developing software interfaces to transition generated synthetic biological test results to other software systems as part of the GINKGO BIOWORKS SD2 PROGRAM. This contract is not set aside for...
This is a $1,074,709 firm fixed-price definitive contract awarded to the Translational Genomics Research Institute (TGen), a non-profit research organization, by the Centers for Disease Control and Prevention (CDC) for the FY 21 BAA TOPIC 8 - TGRI project. The contract has a period of performance through May 14, 2023 and was awarded on May 15, 2021 with no set-aside designation. TGen is a leading institute in precision medicine and translational bioscience, specializing in genomic analyses,...
This is a federal contract awarded by the Centers for Disease Control and Prevention (CDC) to Genome Research LIMITED, doing business as the Wellcome Sanger Institute, a non-profit genomics research organization based in the United Kingdom. The contract, valued at $216,075.00, is for DATAFLO.IO services. It is a definitive, firm fixed-price contract with a completion date of September 29, 2018. The contract does not have a set-aside designation. Genome Research LIMITED has previously received...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...
This is a federal contract award to 10X Genomics, Inc., a life sciences technology company, by the Centers for Disease Control and Prevention (CDC). The $75,072 firm fixed-price contract is for the provision of goods and services related to 10X Genomics' genomic analysis platforms, reagents, instruments, and bioinformatics software. These products and services support single-cell and spatial analysis applications, enabling high-throughput interrogation of biological systems at the single-cell...